Handa Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development of niche portfolios, serving the US and China markets. The company specializes in controlled-release technology and high-barrier formulations, developing 505(b)(2) new drugs and high-barrier Abbreviated New Drug Applications (ANDA) for the US Food and Drug Administration. Key products include Tascenso ODT for multiple sclerosis, Phyrago for leukemia, and Varenicline Tablets for smoking cessation. The company operates through subsidiaries including Handa Neuroscience, LLC, Handa Oncology, LLC, and Handa Therapeutics, LLC. Handa Pharmaceuticals, Inc. was formerly known as Pharmira Laboratories, Inc. and completed the acquisition of Handa Pharmaceuticals, LLC in 2016. The company engages in in-house development, co-development, and out-licensing agreements, partnering with entities such as Par Pharmaceutical, Cycle Pharmaceuticals, and Easywell Biomedicals.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - Specialty & Generic Homepage handapharma.com.tw
Sector Healthcare IR page handapharma.com.tw/investor-relations-en
Tags
specialty pharmaceuticals, controlled-release technology, 505(b)(2) new drugs, high-barrier generics, oncology, neuroscience, smoking cessation, multiple sclerosis, leukemia, cdmo services, Tascenso ODT, Phyrago, Varenicline Tablets, Omcazio, HND-024, HND-020, HND-045, HND-039, Handa Neuroscience LLC, Handa Oncology LLC, Handa Therapeutics LLC, Handa Pharmaceuticals LLC, Hangzhou Handa Pharmaceutical Technology Co. Ltd., Par Pharmaceutical, Cycle Pharmaceuticals, Easywell Biomedicals, Tulex Pharmaceuticals, Taiwan Specialty Pharma, ScinoPharm Taiwan, Taiwania Capital
Press page handapharma.com.tw/news/newsroom

Metrics

Valuation  
Market cap NT$ 14.856B
Market cap (USD) $ 450.891M
P/E 18.85
PEG —
P/BV 2.95
P/S 8.59
P/OCF 29.85
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 17.1%
ROI 13.2%
ROIC 13.2%
Profit margin 43.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 6.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 1.729B 830.674M 1.106B 197.676M 29.235M 28.859M 84.07M 93.69M 538.009M 210.932M 798K 1.679M
Net profit 749.774M 472.743M 726.886M -40.011M -247.67M -282.104M -177.739M -166.507M 293.198M 28.597M -25.127M -11.049M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 86 — — — — — — — — — — —
P/S 8.38 — — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Handa Pharmaceuticals, Inc. (ticker 6620.TWO), listed in Taiwan.

ETFs Holding Handa Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
AVEE 0.01% 2,000 $ 6,607.34 Nov 16, 2026
AVEM 0.00% 207,000 $ 683.859K Nov 16, 2026